Skip to the answer

Epoprostenol Uses, Dosage, Side Effects and Interactions

Brand names
Flolan

Flolan was the first epoprostenol product the FDA approved, in September 1995. The FDA now lists it as discontinued; generic epoprostenol is still listed.

Veletri

Veletri came 12 years after Flolan (June 2008) as an injection. An FDA-approved generic with the same active ingredient is listed.

Epoprostenol is a prostacyclin vasodilator given by intravenous infusion to treat pulmonary arterial hypertension (PAH) and improve exercise capacity.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 19, 2026 Where our facts come from

Quick links

Ask Anything About EpoprostenolType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Epoprostenol in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Epoprostenol (Flolan, Veletri) is a specialist medicine for more advanced pulmonary arterial hypertension (PAH, high blood pressure in the lung arteries). It is a prostacyclin vasodilator that widens the lung arteries and keeps platelets from clumping, in use since about 1995, with FDA-approved generic versions listed. Side effects are common but usually manageable, most often flushing, headache, jaw pain and nausea, and they tend to flare after each dose increase. The one thing to guard against is the infusion stopping, since even a brief interruption from a pump, line or supply problem can bring on rebound pulmonary hypertension, with shortness of breath, dizziness and weakness.

Key Takeaways From the HelloPharmacist Team

  • Expect it to run nonstop through a permanent IV line and small portable pump, which you learn to mix and manage at home.
  • Keep a backup pump and spare supplies with you, and get help right away if the pump or line fails.
  • Use sterile technique with the catheter every time, and call promptly about fever, chills, or redness or pain at the site.
  • Let your PAH team raise the rate gradually over time, and never adjust or pause it yourself, even when side effects flare.

How we write and review this content: our editorial policy

Epoprostenol by the Numbers

Strengths
2
in one form
Makers and packagers
4
Earliest FDA record
1995
Rank by Medicaid prescriptions
#1,291 of 1,682 drugs
More prescriptions than 23% of the 1,682 drugs we measure
1,316 prescriptions, Q1–Q4 2025

Patient Information Guide for Epoprostenol

What It’s Used For

Epoprostenol is used for one main condition.

  • Pulmonary arterial hypertension (PAH, WHO Group 1), to improve exercise capacity (Veletri, intravenous)
  • Pulmonary arterial hypertension (PAH, WHO Group 1), to improve exercise capacity (Epoprostenol for injection, intravenous)
  • Studies were mostly in people with NYHA Class III–IV symptoms, with idiopathic or heritable PAH or PAH linked to connective tissue diseases

How It Works

Epoprostenol is a prostacyclin vasodilator. It directly widens arteries in the lungs and the rest of the body. It also blocks platelet clumping.

Opening up the lung arteries is why it helps in PAH.

Drug Class

Drug Class

  • Prostacycline Vasodilator
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)
  • Prostacycline Vasodilator

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)

None listed for Epoprostenol in the FDA’s index.

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)
  • Vasodilation

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)
  • Prostaglandins I

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Platelet aggregation inhibitors excl. heparin

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

Epoprostenol is a continuous intravenous infusion, usually through a central venous catheter and a portable pump. Your team starts low and raises the rate step by step based on your symptoms and side effects.

It is not taken by mouth, so food does not matter.

  • Reconstitute only as directed, and do not mix with other medicines or solutions.
  • Never stop abruptly or reduce the dose suddenly.
  • Rate changes should be made only under a doctor's direction, except in life-threatening emergencies.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Pulmonary arterial hypertension (high blood pressure in the lung arteries)

Adults · Starting dose Initiate at 2 ng/kg/min and increase in increments of 2 ng/kg/min every 15 minutes or longer until a tolerance limit to the drug is established or further increases are not clinically warranted; if 2 ng/kg/min is not tolerated, use a lower dose

Good to know

Given by continuous intravenous infusion via a central venous catheter; peripheral infusion may be used temporarily until central access is established

Adults · Dose increase Adjust the infusion by 1- to 2-ng/kg/min increments at intervals of at least 15 minutes sufficient to allow assessment of clinical response; in clinical trials increases occurred at intervals of 24 to 48 hours or longer

Good to know

Monitor standing and supine blood pressure and heart rate for several hours after a new rate

Adults · Dose decrease Decrease gradually in 2-ng/kg/min decrements every 15 minutes or longer until the dose-limiting effects resolve

Good to know

Avoid abrupt withdrawal or sudden large reductions in infusion rates

See the Full Dosing Instructions on DailyMed →

Side Effects

Many side effects come from the drug widening blood vessels.

Common side effects

  • Flushing
  • Headache
  • Nausea and vomiting
  • Diarrhea
  • Jaw pain
  • Low blood pressure
  • Anxiety or nervousness
  • Flu-like symptoms

When to get medical help

  • Get help right away if your infusion is interrupted or the pump or line fails. Symptoms like shortness of breath, dizziness or weakness can signal rebound pulmonary hypertension.
  • Call your doctor about signs of infection at the catheter site or in the bloodstream, such as fever, chills, redness or pain.
  • Seek help for fainting, severe dizziness or very low blood pressure.
  • Report unusual bleeding or bruising.
  • Seek urgent care for new or worsening shortness of breath, which can be a sign of fluid in the lungs (pulmonary edema).
  • Call your care team right away if the pump delivers too much or too little medicine.

Act quickly on signs of catheter infection, bleeding, fainting, or worsening breathing. Pump or delivery problems can also cause symptoms of too much or too little drug.

Warnings and Precautions

  • Do not stop suddenly. Interruptions can cause rebound pulmonary hypertension and have been linked to a death in trials.
  • Start treatment where monitoring and emergency care are available.
  • Catheter-related infection and sepsis (a serious bloodstream infection) can occur, so use aseptic technique.
  • Blood thinners are generally given unless contraindicated, to reduce clot risk.
  • Treatment may be needed for years.

Interactions

Some medicines can add to epoprostenol's effects.

  • Diuretics, blood pressure medicines and other vasodilators: further blood pressure drops
  • Antiplatelet drugs or anticoagulants: possible higher bleeding risk
  • Digoxin: levels may rise, which matters if you are prone to digoxin toxicity

Interactions Listed in the FDA-Approved Label

From the Epoprostenol prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Diuretics, antihypertensive agents, or other vasodilators
    What happensAdditional reductions in blood pressure may occur.
  • Antiplatelet agents or anticoagulants
    What happensEpoprostenol may increase the risk of bleeding, although patients in clinical trials were maintained on anticoagulants without evidence of increased bleeding.
  • What happensDigoxin concentrations may be elevated after starting epoprostenol (apparent oral clearance decreased by 15% on the second day), which may be clinically significant in patients prone to digoxin toxicity.
  • What happensApparent oral clearance of furosemide decreased by 13% on the second day of therapy and returned to baseline by day 87; not likely to be clinically significant.
Read the label’s full interactions text

7 DRUG INTERACTIONS Additional reductions in blood pressure may occur when epoprostenol for injection is administered with diuretics, antihypertensive agents, or other vasodilators. When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for epoprostenol for injection to increase the risk of bleeding. However, patients receiving infusions of epoprostenol in clinical trials were maintained on anticoagulants without evidence of increased bleeding. In clinical trials, epoprostenol was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen. In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with epoprostenol was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87. The change in furosemide clearance value is not likely to be clinically significant. However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with epoprostenol, which may be clinically significant in patients prone to digoxin toxicity. · Diuretics, antihypertensive agents, or other vasodilators: reduction in blood pressure · Antiplatelet agents or anticoagulants: increase the risk of bleeding · Patients on digoxin: elevations of digoxin concentrations clinically significant in patients prone to digoxin toxicity

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Not for long-term use with congestive heart failure due to severe left ventricular systolic dysfunction.
  • Not for long-term use if pulmonary edema developed during dose start.
  • Not for people with known hypersensitivity to it or similar compounds.
  • Pregnancy: data are limited and have not established a risk; untreated PAH poses risks to mother and baby.
  • Breastfeeding: no data; weigh benefits and risks with your doctor.
  • Children: safety and effectiveness not established.
  • Older adults: cautious dosing, usually starting low.

Overdose

Too much epoprostenol causes exaggerated effects such as flushing, headache, low blood pressure, fast heartbeat, nausea, vomiting and diarrhea. Treatment usually means lowering the dose. Fatal cases of low oxygen, low blood pressure and respiratory arrest have been reported after overdose, so seek urgent help if you suspect a delivery error.

Half-Life and How Your Body Processes It

Epoprostenol breaks down very quickly in the blood. Its half-life in humans is expected to be no more than about 6 minutes. This is why even short interruptions can cause symptoms. It is extensively metabolized, and most of it leaves in the urine.

Storage

Unopened vials of VELETRI are stable until the date indicated on the package when stored at 68° to 77°F (20° to 25°C).

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Supplements and Herbs That Interact With Epoprostenol

From the licensed clinical database we use, rolled up per supplement, most serious first.

136 supplements and herbal products have documented interactions with Epoprostenol in the licensed clinical database we use.

Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.

  • 4Major
  • 111Moderate
  • 21Minor

See the other 128

Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Nutrients Epoprostenol May Deplete

Nutrients Epoprostenol has been linked with lower levels of, from the licensed clinical database we use.

Epoprostenol has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur. It means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.

Educational information from a licensed clinical database (Natural Medicines), not medical advice. Do not start or stop medications or supplements without professional guidance.

Epoprostenol: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Epoprostenol — the kind of thing our pharmacy team would talk through with you at the counter.

What is epoprostenol used for?

It treats pulmonary arterial hypertension (PAH), which is high blood pressure in the lung arteries. It is used to improve how much activity you can do. Both Veletri and epoprostenol for injection carry this use.

Can I stop epoprostenol suddenly?

No. Because the drug is cleared so quickly, even a short break in the infusion can cause rebound pulmonary hypertension, with shortness of breath, dizziness and weakness. Call your care team right away if your pump or line stops working.

How is epoprostenol given?

It runs continuously into a vein, usually through a central catheter and a small portable pump. Your team starts low and adjusts the rate over time. Follow your prescriber's and the product's instructions closely.

What side effects should I expect?

Flushing, headache, nausea, vomiting, diarrhea, jaw pain and anxiety are common. Many ease with dose adjustments. Call your doctor about fever or catheter-site infection signs, bleeding, fainting or worsening breathing.

Can I take epoprostenol with other medicines?

Tell your care team about everything you take. Water pills, blood pressure medicines and other vasodilators can lower blood pressure further. Blood thinners may raise bleeding risk, and digoxin levels can rise.

Is epoprostenol safe in pregnancy?

Limited data have not established a drug-linked risk. Untreated PAH is risky for both mother and baby, so talk with your doctor about the best plan.

Is epoprostenol available over the counter?

No. Epoprostenol is a prescription medicine: every epoprostenol product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was epoprostenol first available?

The earliest FDA record we hold for epoprostenol is from 1995: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when epoprostenol was first used.

Who makes epoprostenol?

4 companies currently list epoprostenol products in the FDA's NDC Directory, including Actelion Pharmaceuticals US, Inc., Gland Pharma Limited, Mylan Institutional LLC. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

What is the brand name of epoprostenol?

Epoprostenol is the generic name. Its brand names are Flolan and Veletri. Generic versions are listed under the name epoprostenol.

What is the generic name of Flolan?

The generic name of Flolan is epoprostenol. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is epoprostenol?

Epoprostenol belongs to the drug class Prostacycline Vasodilator, its established pharmacologic class on the FDA label.

Is there a generic version of epoprostenol?

Yes. FDA-approved generic versions of epoprostenol are listed in the FDA's National Drug Code Directory. A listing does not prove that every pharmacy stocks one, so your pharmacy can tell you which version it carries.

What strengths does epoprostenol come in?

Epoprostenol is listed in the FDA's National Drug Code Directory in these forms and strengths. Injection (into a vein): 0.5 mg/10 mL and 1.5 mg/10 mL. A listing does not mean every pharmacy stocks every strength.

Is there a epoprostenol shortage?

No. Epoprostenol is not on the FDA's drug shortage list as of Nov 22, 2026. A single pharmacy can still run short for a while without a national shortage, and your pharmacist can tell you what they are seeing.

Where can I read the epoprostenol prescribing information (package insert)?

The full FDA-approved prescribing information for epoprostenol, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from Actelion Pharmaceuticals US, Inc.'s, revised Nov 28, 2022, and links to it on DailyMed.

Is epoprostenol gluten free?

No epoprostenol label we read lists an ingredient made from wheat, barley or rye, the grains that carry gluten, and none names a starch, dextrin or maltodextrin without saying where it comes from. We read the FDA labels of 8 epoprostenol products from 4 companies. A label lists ingredients; it is not a gluten test, so we cannot promise that any product has no gluten. If you have celiac disease, ask the company for a written gluten statement. Our Inactive Ingredient Checker shows each company's epoprostenol by strength and NDC, and whether its label lists a gluten source, lactose, dyes or any other inactive ingredient. See epoprostenol inactive ingredients by company

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Epoprostenol

Skip the scrolling. Ask in your own words and get an answer from Epoprostenol’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Epoprostenol’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Epoprostenol on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, as soon as they can.
Detailed Data & References for Epoprostenol Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Epoprostenol Forms and Strengths (How It Comes)

Epoprostenol comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Epoprostenol inactive ingredients by manufacturer.

Injection

Into a vein
Brands Flolan (the first brand, 1995, discontinued) Veletri (2008)
How this form is used
What it may be used for
  • Veletri is used to treat pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity.
  • Epoprostenol for injection is used to treat pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity.
Important instructions
  • Veletri is given as a continuous intravenous infusion through a central venous catheter using an ambulatory pump.
  • Epoprostenol for injection is given as a continuous intravenous infusion through a central venous catheter using an ambulatory pump.
  • Veletri is reconstituted only with Sterile Water for Injection or Sodium Chloride 0.9% Injection and not mixed with other medicines.
  • Epoprostenol for injection is reconstituted only with Sterile Water for Injection or Sodium Chloride 0.9% Injection and not mixed with other medicines.
Available strengths 2 strengths
8 FDA-listed product records ⓘ

Epoprostenol on the U.S. Market: Products, Makers and Brands

How Epoprostenol appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

4 companies list 8 Epoprostenol product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 1995. The one brand name in the directory today is Veletri; the rest are generics.

1
Dose forms ⓘ
4
Labelers (makers, repackagers, distributors)
2
Brand names ⓘ
8
FDA-listed product records ⓘ
1995
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Powder (6) · Unfinished injection, powder, lyophilized, for solution (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

Actelion Pharmaceuticals US, Inc.25%
Gland Pharma Limited25%
Mylan Institutional LLC25%
Sun Pharmaceutical Industries, Inc.25%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How Widely Epoprostenol Is Used (Medicaid Data)

How many Epoprostenol prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

1,316
Medicaid prescriptions filled (Q1–Q4 2025)
$3.9M paid by Medicaid, before rebates

How commonly is Epoprostenol prescribed? Of the 1,682 medications we measure, Epoprostenol ranks #1,291 by Medicaid prescriptions — more than 23% of them.

Where Epoprostenol ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Epoprostenol product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

epoprostenol 1.5 MG Injection

1,316 Medicaid prescriptions (Q1–Q4 2025) 100% of Epoprostenol prescriptions shown $3.9M paid by Medicaid, before rebates ≈ $2,928 per prescription, before rebates

2 of 6 listed NDCs had Medicaid claims. RxNorm 562502

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 2 of the 6 listed Epoprostenol NDCs had Medicaid claims.

Compare Epoprostenol Products

A representative set of FDA-listed product records for Epoprostenol — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Injection
0.5 mg/10 mL Intravenous Actelion Pharmaceuticals US, Inc. NDA View NDC →
1.5 mg/10 mL Intravenous Actelion Pharmaceuticals US, Inc. NDA View NDC →
0.5 mg/10 mL Intravenous Gland Pharma Limited ANDA View NDC →
1.5 mg/10 mL Intravenous Gland Pharma Limited ANDA View NDC →
0.5 mg/10 mL Intravenous Mylan Institutional LLC ANDA View NDC →
1.5 mg/10 mL Intravenous Mylan Institutional LLC ANDA View NDC →
0.5 mg/10 mL Intravenous Sun Pharmaceutical Industries, Inc. ANDA View NDC →
1.5 mg/10 mL Intravenous Sun Pharmaceutical Industries, Inc. ANDA View NDC →

Showing 8 of 8 products — FDA National Drug Code Directory. See every product, package size and price: browse all 8 Epoprostenol NDCs →

Epoprostenol Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Epoprostenol recalls since July 2021.

✅No Epoprostenol recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Epoprostenol in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
1
Strengths
2
Forms in current FDA listings
1 of 1
In current FDA listings No current FDA listing
Ingredient (IN) Epoprostenol RxCUI 8814
  1. Dose form (SCDF) Injection RxCUI 1789858
    In current FDA listings
    Its 2 strengths (SCD)

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Epoprostenol Brand Names

Epoprostenol has 2 brand names on record: Flolan and Veletri. Veletri is in the FDA’s product directory today; Flolan is not. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Flolan the first brand, 1995, discontinued Veletri 2008

Who Makes Epoprostenol: Manufacturers and Labelers

4 companies list Epoprostenol products with the FDA. By number of product records, the largest are Actelion Pharmaceuticals US, Inc., Gland Pharma Limited, Mylan Institutional LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Actelion Pharmaceuticals US, Inc. 2 Gland Pharma Limited 2 Mylan Institutional LLC 2 Sun Pharmaceutical Industries, Inc. 2

Sources for This Epoprostenol Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Nov 28, 2022, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Epoprostenol.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 4 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
4
Finished products in the current FDA directory
8
Companies listing them (makers, repackagers, distributors)
4
FDA labeler codes behind them ⓘ
4
Linked representative label ⓘ
Actelion Pharmaceuticals US, Inc.
Linked label effective
Nov 28, 2022
Composite sections available
22
Linked SPL Set ID
df502787-46ec-4dd1-a2c0-be90f6d95a5d
Linked SPL Document ID
39e8b7f8-f82a-4083-a284-ce571a87ce97
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Actelion Pharmaceuticals US, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →